BRPI0820258A2 - composto, composições de vacina e farmacêutica, e , métodos para estimular uma resposta imune em um indivíduo e para tratar um indivíduo - Google Patents
composto, composições de vacina e farmacêutica, e , métodos para estimular uma resposta imune em um indivíduo e para tratar um indivíduoInfo
- Publication number
- BRPI0820258A2 BRPI0820258A2 BRPI0820258A BRPI0820258A BRPI0820258A2 BR PI0820258 A2 BRPI0820258 A2 BR PI0820258A2 BR PI0820258 A BRPI0820258 A BR PI0820258A BR PI0820258 A BRPI0820258 A BR PI0820258A BR PI0820258 A2 BRPI0820258 A2 BR PI0820258A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- vaccine
- stimulating
- treating
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99622607P | 2007-11-07 | 2007-11-07 | |
| EP07291336.1 | 2007-11-07 | ||
| US60/996226 | 2007-11-07 | ||
| EP07291336A EP2058011A1 (en) | 2007-11-07 | 2007-11-07 | Nkt cell activating gycolipids covalently bound antigens and/or drug |
| PCT/EP2008/065179 WO2009060086A2 (en) | 2007-11-07 | 2008-11-07 | Increase of immune response and targeting by antigens and/or drug linkage |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0820258A2 true BRPI0820258A2 (pt) | 2017-04-04 |
| BRPI0820258B1 BRPI0820258B1 (pt) | 2020-08-18 |
| BRPI0820258B8 BRPI0820258B8 (pt) | 2021-05-25 |
Family
ID=39110389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0820258A BRPI0820258B8 (pt) | 2007-11-07 | 2008-11-07 | composto, composições de vacina, e, uso de um composto |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8642565B2 (pt) |
| EP (2) | EP2058011A1 (pt) |
| JP (1) | JP5404639B2 (pt) |
| CN (1) | CN101918033B (pt) |
| AU (1) | AU2008324118B2 (pt) |
| BR (1) | BRPI0820258B8 (pt) |
| CA (1) | CA2705067C (pt) |
| DK (1) | DK2231196T3 (pt) |
| ES (1) | ES2584928T3 (pt) |
| IL (1) | IL205583A (pt) |
| MX (1) | MX2010005113A (pt) |
| PT (1) | PT2231196T (pt) |
| RU (1) | RU2548685C2 (pt) |
| WO (1) | WO2009060086A2 (pt) |
| ZA (1) | ZA201003286B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916164B2 (en) | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
| RU2537188C2 (ru) | 2007-12-05 | 2014-12-27 | Виттисель | Композиции и способы для усиления имунного ответа на антигены |
| TWI633112B (zh) * | 2012-03-19 | 2018-08-21 | 馬克斯普朗克科學發展組織 | 醣類－醣脂類結合性疫苗 |
| IN2015KN00492A (pt) * | 2012-07-26 | 2015-07-17 | Callaghan Innovation Res Ltd | |
| WO2014088432A1 (en) * | 2012-12-06 | 2014-06-12 | Callaghan Innovation Research Limited | Conjugate compounds |
| WO2015187040A1 (en) * | 2014-06-05 | 2015-12-10 | Regan James Anderson | Amino sphingoglycolipid analogues |
| EP3925963A1 (en) * | 2020-06-18 | 2021-12-22 | Helmholtz-Zentrum für Infektionsforschung GmbH | Phytosphingosine derivatives as adjuvants in immune stimulation |
| WO2022061096A1 (en) * | 2020-09-17 | 2022-03-24 | Board Of Regents, The University Of Texas System | Pharmaceutical compositions of niclosamide and a protein |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1592453A (en) | 1976-05-14 | 1981-07-08 | Smith Kline French Lab | Aminoalkyl esters of carbarimidothioic acid and compositions having immunosuppressant activity |
| US5242800A (en) | 1990-01-30 | 1993-09-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Receptor for pathogenic fungi |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| TW261533B (pt) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| AU683026B2 (en) | 1992-10-22 | 1997-10-30 | Kirin Pharma Kabushiki Kaisha | Novel shingoglycolipid and use thereof |
| EP0694558B1 (en) | 1993-04-15 | 1999-01-27 | Kirin Beer Kabushiki Kaisha | Novel sphingoglycolipid and use thereof |
| CZ298895A3 (en) | 1993-05-14 | 1996-04-17 | Cytel Corp | Compound analogous to sialyl lex, pharmaceutical composition containing thereof and process for preparing lactosammonium salt |
| US6054433A (en) | 1994-11-03 | 2000-04-25 | The Regents Of The University Of California | Methods and compositions for stimulating tissue growth and epithelial moisturization |
| US5785975A (en) | 1995-06-26 | 1998-07-28 | Research Triangle Pharmaceuticals | Adjuvant compositions and vaccine formulations comprising same |
| EP0821068A3 (en) | 1996-03-29 | 1999-06-02 | Rohm And Haas Company | Novel sphingolipids and a process thereto |
| US6417167B1 (en) | 1997-02-05 | 2002-07-09 | Kirin Beer Kabushiki Kaisha | Lyophilized compositions containing shingoglycolipid and process for preparing them |
| CA2280130C (en) | 1997-02-05 | 2007-12-18 | Kirin Beer Kabushiki Kaisha | Lyophilized compositions containing sphingoglycolipid and process for preparing them |
| JP3495740B2 (ja) | 1997-04-10 | 2004-02-09 | 麒麟麦酒株式会社 | α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤 |
| US6492337B1 (en) | 1997-12-30 | 2002-12-10 | A+ Science Ab | Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complication |
| DE69943314D1 (de) | 1998-02-12 | 2011-05-12 | Kapil N Bhalla | Sphingolipid-derivate und verfahren zu deren verwendung |
| US20030157113A1 (en) | 1999-12-28 | 2003-08-21 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| AU2001252599A1 (en) | 2000-04-28 | 2001-11-12 | Orient Cancer Therapy Co., Ltd. | Remedies for cancer |
| JP4410913B2 (ja) | 2000-06-12 | 2010-02-10 | 壽製薬株式会社 | 新規糖脂質誘導体の製造方法 |
| WO2001098317A2 (en) | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| AR034413A1 (es) | 2000-08-25 | 2004-02-25 | Nestor Abel Chamoles | Metodo para determinar la actividad de las enzimas lisosomales |
| EP1434859A2 (en) | 2001-07-25 | 2004-07-07 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| KR100549866B1 (ko) | 2001-08-22 | 2006-02-08 | 고려대학교 산학협력단 | 암치료 및 예방 제제 |
| US7459461B2 (en) * | 2001-10-19 | 2008-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Phosphonic acid compounds as inhibitors of serine proteases |
| KR20050043736A (ko) | 2001-11-06 | 2005-05-11 | 오리엔트 캔서 세라피 컴퍼니 리미티드 | 항암 조성물 |
| US7273853B2 (en) | 2002-05-13 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | 6-11 bicyclic ketolide derivatives |
| AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| AU2003225891A1 (en) | 2003-03-20 | 2004-11-19 | Brigham Young University | 6"-amino-6"-deoxygalactosylceramides |
| GB0314682D0 (en) | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| CA2560969A1 (en) | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
| EP1784196B1 (en) | 2004-08-27 | 2016-12-21 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
| CA2578052C (en) | 2004-09-03 | 2013-08-13 | The University Of Chicago | Methods of activating nkt cells |
| US7534434B2 (en) | 2004-12-28 | 2009-05-19 | The Rockefeller University | Glycolipids and analogues thereof as antigens for NK T cells |
| PT1848813E (pt) | 2005-01-28 | 2013-07-15 | Scripps Research Inst | Activação de glicolípidos bacterianos de células nkt restritas ao cd1d |
| KR100764678B1 (ko) | 2005-07-13 | 2007-10-09 | 재단법인서울대학교산학협력재단 | 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물 |
| BRPI0617687A2 (pt) | 2005-10-25 | 2011-08-02 | Ludwig Inst Cancer Res | composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica |
| WO2007051004A2 (en) * | 2005-10-28 | 2007-05-03 | The Brigham And Women's Hospital, Inc. | Conjugate vaccines for non-proteinaceous antigens |
| DK2056842T3 (da) * | 2006-04-07 | 2013-01-14 | Univ Chicago | Modificeret galactosylceramid til behandling af cancerøse sygdomme |
| EP2040541B1 (en) | 2006-06-30 | 2016-03-23 | The Scripps Research Institute | Adjuvants and methods of use |
| EP1938836A1 (en) | 2006-12-28 | 2008-07-02 | Universite Rene Descartes (Paris V) | Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells |
| RU2537188C2 (ru) * | 2007-12-05 | 2014-12-27 | Виттисель | Композиции и способы для усиления имунного ответа на антигены |
-
2007
- 2007-11-07 EP EP07291336A patent/EP2058011A1/en not_active Withdrawn
-
2008
- 2008-11-07 CA CA2705067A patent/CA2705067C/en active Active
- 2008-11-07 CN CN2008801227231A patent/CN101918033B/zh active Active
- 2008-11-07 ES ES08846406.0T patent/ES2584928T3/es active Active
- 2008-11-07 MX MX2010005113A patent/MX2010005113A/es active IP Right Grant
- 2008-11-07 RU RU2010122946/04A patent/RU2548685C2/ru active
- 2008-11-07 DK DK08846406.0T patent/DK2231196T3/en active
- 2008-11-07 JP JP2010532611A patent/JP5404639B2/ja active Active
- 2008-11-07 BR BRPI0820258A patent/BRPI0820258B8/pt active IP Right Grant
- 2008-11-07 WO PCT/EP2008/065179 patent/WO2009060086A2/en not_active Ceased
- 2008-11-07 US US12/741,980 patent/US8642565B2/en not_active Expired - Fee Related
- 2008-11-07 PT PT88464060T patent/PT2231196T/pt unknown
- 2008-11-07 AU AU2008324118A patent/AU2008324118B2/en active Active
- 2008-11-07 EP EP08846406.0A patent/EP2231196B1/en active Active
-
2010
- 2010-05-06 IL IL205583A patent/IL205583A/en active IP Right Grant
- 2010-05-10 ZA ZA2010/03286A patent/ZA201003286B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009060086A3 (en) | 2009-12-10 |
| RU2010122946A (ru) | 2011-12-20 |
| CN101918033B (zh) | 2012-12-05 |
| BRPI0820258B8 (pt) | 2021-05-25 |
| CA2705067C (en) | 2016-08-16 |
| WO2009060086A2 (en) | 2009-05-14 |
| CN101918033A (zh) | 2010-12-15 |
| EP2058011A1 (en) | 2009-05-13 |
| IL205583A (en) | 2014-05-28 |
| IL205583A0 (en) | 2010-11-30 |
| EP2231196A2 (en) | 2010-09-29 |
| US20100330111A1 (en) | 2010-12-30 |
| JP2011503034A (ja) | 2011-01-27 |
| JP5404639B2 (ja) | 2014-02-05 |
| ZA201003286B (en) | 2011-03-30 |
| AU2008324118B2 (en) | 2013-05-16 |
| EP2231196B1 (en) | 2016-05-25 |
| AU2008324118A1 (en) | 2009-05-14 |
| DK2231196T3 (en) | 2016-08-22 |
| RU2548685C2 (ru) | 2015-04-20 |
| US8642565B2 (en) | 2014-02-04 |
| BRPI0820258B1 (pt) | 2020-08-18 |
| ES2584928T3 (es) | 2016-09-30 |
| MX2010005113A (es) | 2010-10-07 |
| CA2705067A1 (en) | 2009-05-14 |
| PT2231196T (pt) | 2016-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0820258A2 (pt) | composto, composições de vacina e farmacêutica, e , métodos para estimular uma resposta imune em um indivíduo e para tratar um indivíduo | |
| BRPI0905725A2 (pt) | vacina, embalagem farmacêutica e processo para criar uma resposta imune em tecido de indivíduo | |
| BRPI0920283A2 (pt) | composição e método para induzir resposta imunológica humoral | |
| BRPI0920282A2 (pt) | composição e método para induzir resposta imunológica humoral | |
| BRPI0810806A2 (pt) | Método para tratar uma lesão cutânea em um indivíduo | |
| BR112014010186A2 (pt) | formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal | |
| BRPI0812562A2 (pt) | composições terapêuticas anti-cd20 e métodos | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| BRPI0807544A2 (pt) | Sólido farmacêutico e dose de vacina | |
| BR112012019757A2 (pt) | composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular | |
| PT2729151T (pt) | Composição farmacêutica, métodos de tratamento e suas utilizações | |
| BRPI0917358A2 (pt) | formulação farmacêutica de liberação controlada e método. | |
| SI3447061T1 (sl) | Farmacevtska formulacija, ki obsega fosforamidni derivat 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka | |
| BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
| DK2227539T3 (da) | Sammensætning til menneske- og/eller dyreernæring, anvendelser deraf og gær | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BRPI0822337A2 (pt) | Folatos, composições e usos dos mesmos | |
| CY2016053I1 (el) | Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας | |
| ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
| PT2340042E (pt) | Métodos e composições para o tratamento de cancro | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| BRPI0906997A2 (pt) | Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica | |
| FR2933700B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
| BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
| BRPI1007721A2 (pt) | composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ABIVAX (FR) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C07H 15/06 (2006.01), A61K 39/385 (2006.01), A61K |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |